

Siliq (brodalumab)
Effective 01/01/2026

Plan	<input type="checkbox"/> MassHealth UPPL <input checked="" type="checkbox"/> Commercial/Exchange	Program Type	<input checked="" type="checkbox"/> Prior Authorization <input type="checkbox"/> Quantity Limit <input type="checkbox"/> Step Therapy
Benefit	<input checked="" type="checkbox"/> Pharmacy Benefit <input type="checkbox"/> Medical Benefit		
Specialty Limitations	This medication has been designated specialty and must be filled at a contracted specialty pharmacy.		
Contact Information	Medical Benefit Pharmacy Benefit	Phone: 833-895-2611 Phone: 800-711-4555	Fax: 888-656-6671 Fax: 844-403-1029
Exceptions	N/A		

Overview

Siliq (brodalumab) is a human interleukin-17 receptor A (IL-17RA) antagonist indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy or phototherapy and have failed to respond or have lost response to other systemic therapies.

Coverage Guidelines

Authorization may be granted for members new to the plan within the past 90 days who are currently receiving treatment with the requested medication, excluding when the product is obtained as samples or via manufacturer's patient assistance programs

OR

Authorization may be granted when all the following criteria have been met:

Moderate to severe plaque psoriasis

1. Diagnosis of moderate to severe plaque psoriasis
2. At least 3% of body surface area (BSA) is affected OR crucial body areas (e.g., hands, feet, face, neck, scalp, genitals/groin, intertriginous areas) are affected.
3. Member meets ONE of the following criteria:
 - a. Minimum duration of 4-week trial and failure, intolerance, or contraindication to ONE of the following topical therapies:
 - i. Corticosteroids (e.g., betamethasone, clobetasol)
 - ii. Vitamin D analogs (e.g., calcitriol, calcipotriene)
 - iii. Tazarotene
 - iv. Calcineurin inhibitors (e.g., tacrolimus, pimecrolimus)
 - v. Anthralin
 - vi. Coal tar
 - b. Member has severe psoriasis that warrants a biologic DMARD as first-line therapy.
4. Trial and failure, intolerance, or contraindication to TWO of the following:
 - a. Cimzia
 - b. Enbrel
 - c. Humira (AbbVie), Hadlima, Simlandi, Yuflyma
 - d. Otezla

- e. Skyrizi
- f. Sotyktu
- g. Selarsdi, Steqeyma, Yesintek
- h. Tremfya

5. Trial and failure, intolerance, or contraindication to BOTH of the following:

- a. Taltz
- b. Bimzelx

Continuation of Therapy

Requests for reauthorization will be approved when the following criteria are met:

1. Documentation is submitted supporting an improvement in member's condition as evidenced by low disease activity or improvement in signs and symptoms of the condition

Limitations

1. Initial approvals and reauthorizations will be granted for 24 months
2. The following quantity limits apply:

Drug Name and Dosage Form	Quantity Limit
Siliq prefilled syringe	2 syringes per 28 days

References

1. Elmets CA, Korman NJ, Farley Prater E, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. *J Am Acad Dermatol* 2021;84:432-70.
2. Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. *J Am Acad Dermatol* 2019;80:1029-72.
3. Siliq (brodalumab) [prescribing information]. Bridgewater, NJ: Bausch Health US, LLC; August 2024.

Review History

02/26/18 – Reviewed

06/01/18 - Implemented

02/20/19 – Updated

11/20/19 – Added Skyrizi as a preferred trial for PS.

11/15/2023 – Reviewed and Updated at Nov P&T; 5% BSA changed to at least 3%. Removed TB requirement. Updated preferred agents from having prior use with ALL the preferred products (Cosentyx, Enbrel, Humira, Otezla, Skyrizi and Stelara) to having prior use with 3 of the following agents: Cimzia, Enbrel, Humira or biosimilars, Skyrizi, Stelara, Tremfya AND Cosentyx. Updated topical therapies. Effective 1/1/2024

10/09/2024 – Reviewed and updated for October P&T. Updated criteria for conventional therapies to remove submission of documentation requirement. Added Amjevit (Nuvaila) as a preferred adalimumab product. Updated biologic step options to include Otezla and Wezlana. Removed Cosentyx step through requirement and replaced with Taltz. Updated reauthorization criteria to require documentation of improvement. Removed appendix from policy. Effective 1/1/2025.

04/09/2025 – Reviewed and updated for April P&T. Updated criteria for plaque psoriasis to require step through with two preferred immunomodulators AND Taltz AND Bimzelx. Added quantity limit to the Limitations section of the policy. Effective 07/01/2025.

06/11/2025 – Reviewed and updated for June P&T. Updated criteria for plaque psoriasis to include Sotyktu as a previous trial option. Effective 09/01/2025.

09/10/2025 - Reviewed and updated at September P&T. Added Yesintek as an Ustekinumab trial option. Effective 10/15/2025.



10/08/2025 – Reviewed and updated at October P&T. Updated policy to reflect that Selarsdi, Steqeyma and Yesintek are the preferred Ustekinumab trial options. Updated policy to reflect that Humira, Hadlima, Simlandi and Yuflyma are the preferred adalimumab trial options. Effective 01/01/2026.

